PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced the installation of an EOS imaging system at Children's Mercy Hospitals and Clinics in Kansas City, Mo.
Children’s Mercy Hospital and Clinics are nationally recognized for delivering high quality, compassionate pediatric care, ranking among the nation’s top pediatric hospitals. According to U.S. News and World Report’s 2014-15 “Best Children’s Hospitals,” Children’s Mercy was top rated in nine of its 10 specialties, including a top-15 listing in centers for pediatric orthopedics. Parents Magazine ranked the hospital fourth of the top 10 children’s hospitals in the U.S.
The EOS system provides full-body images of patients in a natural standing or seated position in both 2D and 3D with 50% to 85% less dose than Digital Radiology and 95% less dose than basic CT scans, in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction. This comprehensive yet low dose imaging makes EOS imaging ideal for pediatric patients who require frequent treatment monitoring.
Marie Meynadier, CEO of EOS imaging, “This installation at Children’s Mercy makes EOS the imaging system of choice for nearly half of the top 20 pediatric orthopedics programs in the U.S. Orthopedic surgeons and specialists from across the country recognize the importance of treatment monitoring for scoliosis and other osteo-articular conditions using imaging at the lowest possible levels of radiation. We are proud to count Children’s Mercy in this responsible group of hospitals that use EOS to deliver the best available orthopedic care for their young patients.”
For more information, please visit www.eos-imaging.com.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 90 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 101 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 1st half of 2014, on July 22, 2014 (after market).
EOS imaging will participate to the French Life Sciences Days